INDP — Indaptus Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1857044 ·
Last close
$3.29
Market Cap
$438.37M
52W High
$5.96
52W Low
$0.92
ADV30
1,561,640
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -1,808,866 | -1,794,863 | 11,987,956 | 7,553,820 | 615,426 |
| Mar 2026 | 0 | — | -2,159,588 | -2,541,070 | 2,180,856 | 1,497,635 | 932,999 |
| Dec 2025 | 0 | — | -8,155,704 | -8,112,450 | 9,310,168 | 8,507,628 | 6,158,575 |
| Sep 2025 | 0 | — | -2,648,487 | -2,975,117 | 6,840,052 | 5,825,639 | 2,234,325 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-16,786,122
Investing CF
$0
Financing CF
$14,392,736
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-21.41
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-83,829,169
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-17,420,542
Pretax Income TTM
$-18,857,556
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -19,833,513 | -20,848,916 | 9,310,168 | 6,158,575 | 3,151,593 | -14,823,256 |
| Dec 2024 | 0 | -15,365,751 | -15,022,027 | 7,338,756 | 3,393,881 | 3,944,875 | -12,323,188 |
| Dec 2023 | 0 | -16,378,474 | -15,423,471 | 14,923,878 | 2,847,380 | 12,076,498 | -13,405,315 |
| Dec 2022 | 0 | -14,910,906 | -14,322,798 | 28,063,806 | 3,433,341 | 24,630,465 | -13,078,347 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.39
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NIKA | NIKA PHARMACEUTICALS, INC | $429.91M | $0.41 | — |
| PRTA | PROTHENA CORP PUBLIC LTD CO | $447.66M | $8.72 | — |
| DMAC | DiaMedica Therapeutics Inc. | $448.66M | $8.32 | — |
| MPLT | MapLight Therapeutics, Inc. | $456.15M | $10.45 | — |
| IRD | Opus Genetics, Inc. | $420.14M | $5.05 | — |
News headlines (Yahoo Finance, 1h cache)
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-15 11:00 · Yahoo
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
2026-09-25 03:23 · Yahoo
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-13 11:00 · Yahoo
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
2025-12-29 12:00 · Yahoo
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
2025-11-17 13:00 · Yahoo
Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2025-11-12 13:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.